Convergence Investment Partners’s 10x Genomics TXG Stock Holding History

Convergence Investment Partners’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.85M	Buy	+74,234	New	+$1.95M	0.27%	130

Other funds holding TXG

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Caprock Group Boise, Idaho $5.22B AUM 42.47% 1-Year Est. Return

Financial Consulate Hunt Valley, Maryland $899M AUM 20.23% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

CPC

Cookson Peirce & Co Pittsburgh, Pennsylvania $3.04B AUM 94.11% 1-Year Est. Return

MCP

Mirador Capital Partners Pleasanton, California $817M AUM 42.46% 1-Year Est. Return

Convergence Investment Partners's TXG Position: Q2 2026 in Review

Convergence Investment Partners opened a new position in 10x Genomics (TXG) in Q2 2026: 74,234 shares worth $2.85M. The stake represents 0.27% of the portfolio and ranks #130 among its holdings.

98 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

Convergence Investment Partners held 74,234 shares of 10x Genomics worth $2.85M as of Q2 2026.
10x Genomics was a new Convergence Investment Partners position in Q2 2026.
10x Genomics made up 0.27% of Convergence Investment Partners's portfolio in Q2 2026, its #130 holding.
98 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Convergence Investment Partners's 13F filing for Q2 2026, filed 31 Jul 2026.